By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Nanoparticle Research. According to news reporting from Jiangsu, People's Republic of China, by NewsRx journalists, research stated, "Studies from hematopoietic origin malignancies have demonstrated that multiple myeloma contain a rare population of cancer stem cells (CSCs) that are responsible for tumor multiresistance and recurrence. The goal of this study was to investigate targeted therapeutic effect of anti-ABCG2 monoclonal antibody (McAb) combined with silver nanoparticles (AgNPs) and vincristine (VCR) on myeloma CSCs."
The news correspondents obtained a quote from the research from Southeast University, "The characteristics of CD44(+) CD24(-) cells that were isolated from the SP2/0 cells using magnetic activated cell sorting system were first identified. The results showed that the CD44(+) CD24(-) cells exhibited higher proliferation, more colony formation, more side population fraction, and stronger tumorigenicity in BALB/c mice than the control cells. Moreover, CD44(+) CD24(-) cells markedly up-regulated the ABCG2 expression, however, anti-ABCG2 McAb combined with AgNPs and VCR effectively inhibited the CD44(+) CD24(-) cell growth and prolonged the survival of myeloma-bearing mice. We concluded that the CD44(+) CD24(-) cells in mouse myeloma SP2/0 cell line posses CSC properties."
According to the news reporters, the research concluded: "Anti-ABCG2 McAb combined with AgNPs and VCR provide an efficient targeted therapeutic method for inhibiting myeloma CD44(+) CD24(-) CSC growth in mice."
For more information on this research see: Targeted therapeutic effect of anti-ABCG2 antibody combined with nano silver and vincristine on mouse myeloma cancer stem cells. Journal of Nanoparticle Research, 2013;15(12):1-12. Journal of Nanoparticle Research can be contacted at: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands. (Springer - www.springer.com; Journal of Nanoparticle Research - www.springerlink.com/content/1388-0764/)
Our news journalists report that additional information may be obtained by contacting J. Dou, Southeast Univ, Zhongda Hosp, Dept. of Oncol, Nanjing 210009, Jiangsu, People's Republic of China. Additional authors for this research include X.F. He, Y.J. Liu, Z.H. Huang, C.P. Yang, F.F. Shi, D.Y. Chen and N. Gu (see also Nanoparticle Research).
Keywords for this news article include: Asia, Cancer, Jiangsu, Oncology, Nanoparticle Research, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC